Immunotherapy in advanced anal cancer: Is the beginning of a new era?

[1]  C. Borg,et al.  Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies , 2022, European Journal of Cancer.

[2]  P. Ascierto,et al.  Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. , 2022, The lancet. Gastroenterology & hepatology.

[3]  F. Ciardiello,et al.  Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. , 2022, Clinical colorectal cancer.

[4]  F. Tong,et al.  The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy , 2021, Frontiers in Oncology.

[5]  M. Fassan,et al.  Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study , 2021, Journal for ImmunoTherapy of Cancer.

[6]  C. Porta,et al.  Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives. , 2021, Cancer treatment reviews.

[7]  S. Salas,et al.  957O Long-term follow-up of patients (pts) with human papillomavirus (HPV)–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1 , 2021, Annals of Oncology.

[8]  N. Normanno,et al.  Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. , 2021, JAMA oncology.

[9]  C. Borg,et al.  Present and Future Research on Anal Squamous Cell Carcinoma , 2021, Cancers.

[10]  S. Steigen,et al.  Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J. Hubbard,et al.  Research on Anal Squamous Cell Carcinoma: Systemic Therapy Strategies for Anal Cancer , 2021, Cancers.

[12]  A. Jácome,et al.  Emerging and Experimental Agents for Anal Cancer: What is New? , 2021, Journal of experimental pharmacology.

[13]  M. Abba,et al.  A clinical and molecular portrait of non-metastatic anal squamous cell carcinoma , 2021, Translational oncology.

[14]  J. Becker,et al.  Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. , 2021, Cancer treatment reviews.

[15]  J. Lack,et al.  TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers , 2021, Nature Medicine.

[16]  C. Borg,et al.  Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma , 2020, Therapeutic advances in medical oncology.

[17]  S. Salas,et al.  Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies , 2020, Journal for ImmunoTherapy of Cancer.

[18]  Y. Najjar,et al.  407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors , 2020 .

[19]  K. Spindler,et al.  LBA42 POD1UM-202: Phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy , 2020 .

[20]  C. Berking,et al.  Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma , 2020, Cancers.

[21]  G. Martini,et al.  How I treat anal squamous cell carcinoma , 2020, ESMO open.

[22]  I. Wistuba,et al.  403MO Atezolizumab in combination with bevacizumab for patients with unresectable/metastatic anal cancer , 2020 .

[23]  C. Borg,et al.  Anti-Telomerase CD4+ Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials , 2020, International journal of molecular sciences.

[24]  F. Ciardiello,et al.  Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer , 2020, ESMO Open.

[25]  J. Tabernero,et al.  Clinical development of therapies targeting TGFβ: current knowledge and future perspectives. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  L. Rajdev,et al.  Immunotherapy in Anal Cancer , 2020, Current Oncology Reports.

[27]  A. Benson,et al.  International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Heslop,et al.  Virus-specific T cells for malignancies - then, now and where to? , 2020, Current stem cell reports.

[29]  P. Ascierto,et al.  Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies. , 2020 .

[30]  B. Pessia,et al.  Squamous cell anal cancer: Management and therapeutic options , 2020, Annals of medicine and surgery.

[31]  J. Debus,et al.  RADIANCE – Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial , 2020, Clinical and translational radiation oncology.

[32]  F. Bidard,et al.  Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial , 2020, BMC Cancer.

[33]  J. Squire,et al.  Emerging role of PTEN loss in evasion of the immune response to tumours , 2020, British Journal of Cancer.

[34]  M. Fakih,et al.  A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer , 2020, Oncotarget.

[35]  A. Nicolas,et al.  Mechanistic Signatures of Human Papillomavirus Insertions in Anal Squamous Cell Carcinomas , 2019, Cancers.

[36]  Sung-Bae Kim,et al.  Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma , 2019, Annals of Oncology.

[37]  W. Gu,et al.  PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition , 2019, Front. Immunol..

[38]  K. Almhanna,et al.  Anal cancer and immunotherapy-are we there yet? , 2019, Translational gastroenterology and hepatology.

[39]  J. Gartner,et al.  T-Cell Receptor Gene Therapy for Human Papillomavirus–Associated Epithelial Cancers: A First-in-Human, Phase I/II Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  G. Vandermeulen,et al.  Cancer DNA vaccines: current preclinical and clinical developments and future perspectives , 2019, Journal of experimental & clinical cancer research : CR.

[41]  Young Uk Kim,et al.  Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer: A Phase 2 Clinical Trial , 2019, JAMA oncology.

[42]  S. Rosenberg,et al.  A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus–associated Epithelial Cancers , 2018, Clinical Cancer Research.

[43]  D. Schadendorf,et al.  Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[44]  C. Borg,et al.  Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. , 2018, The Lancet. Oncology.

[45]  V. Morris,et al.  Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[46]  C. Rödel,et al.  Anal squamous cell carcinoma - State of the art management and future perspectives. , 2018, Cancer treatment reviews.

[47]  A. Zhavoronkov,et al.  Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy , 2018, Nature Communications.

[48]  J. Hesser,et al.  Using immunotherapy to boost the abscopal effect , 2018, Nature Reviews Cancer.

[49]  Joe Y. Chang,et al.  Combining radiation plus immunotherapy to improve systemic immune response. , 2018, Journal of thoracic disease.

[50]  M. Sawyer,et al.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Aroop Sircar,et al.  Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β , 2018, Science Translational Medicine.

[52]  F. Bidard,et al.  Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study) , 2017, BMC Cancer.

[53]  Jing Wang,et al.  Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal , 2017, Molecular Cancer Research.

[54]  Toby C. Cornish,et al.  Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy , 2017, JAMA oncology.

[55]  P. Sharma,et al.  Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. , 2017, The Lancet. Oncology.

[56]  K. Emancipator,et al.  Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  C. Rödel,et al.  Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy , 2017, Oncoimmunology.

[58]  V. Goh,et al.  Biomarkers in anal cancer: from biological understanding to stratified treatment , 2016, British Journal of Cancer.

[59]  G. Getz,et al.  Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma , 2016, Clinical Cancer Research.

[60]  S. Demaria,et al.  Current clinical trials testing the combination of immunotherapy with radiotherapy , 2016, Journal of Immunotherapy for Cancer.

[61]  C. Eng,et al.  Epidermal growth factor receptor inhibition in metastatic anal cancer , 2016, Anti-cancer drugs.

[62]  James X. Sun,et al.  Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[63]  G. Coukos,et al.  Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  L. Emens,et al.  The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies , 2015, Cancer Immunology Research.

[65]  J. Beijnen,et al.  HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53 , 2015, British Journal of Cancer.

[66]  E. Høgdall,et al.  Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  J. Bosset,et al.  DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  Laurence Zitvogel,et al.  Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.

[69]  M. Moore,et al.  Epidermal growth factor receptor expression in anal canal carcinoma. , 2005, American journal of clinical pathology.

[70]  G. Demers,et al.  Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis , 1996, Nature Medicine.